InvestSMART

Imugene Limited (ASX: IMU) - Announcements

- Current share price for IMU : $0.071

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$37 Imugene Corporate Presentation 15 Mar 2023 11:55AM $0.120 $0.071 fallen by 40.83%
$37 Notice Under Section 708A 10 Mar 2023 5:15PM $0.125 $0.071 fallen by 43.20%
$37 Notification regarding unquoted securities - IMU 10 Mar 2023 5:08PM $0.125 $0.071 fallen by 43.20%
$37 Application for quotation of securities - IMU 10 Mar 2023 5:04PM $0.125 $0.071 fallen by 43.20%
$37 Change of Registered Office 8 Mar 2023 9:49AM $0.135 $0.071 fallen by 47.41%
$37 First Patients Dosed in Combination Study of VAXINIA 3 Mar 2023 9:41AM $0.135 $0.071 fallen by 47.41%
$37 Imugene appoints CFO Mike Tonroe as Company Secretary 2 Mar 2023 2:05PM $0.130 $0.071 fallen by 45.38%
$37 Half Yearly Report and Accounts 28 Feb 2023 12:07PM $0.130 $0.071 fallen by 45.38%
$37 Application for quotation of securities - IMU 22 Feb 2023 5:30PM $0.135 $0.071 fallen by 47.41%
$37 Imugene PD1-Vaxx Immunotherapy Patent Granted in the US 10 Feb 2023 8:41AM $0.135 $0.071 fallen by 47.41%
$37 Imugene VAXINIA trial advances to Combination Cohort 2 Feb 2023 9:50AM $0.140 $0.071 fallen by 49.29%
$37 Quarterly Activities/Appendix 4C Cash Flow Report 27 Jan 2023 9:51AM $0.150 $0.071 fallen by 52.67%
$37 HER-Vaxx and CF33 Platforms Featured at ASCO Symposium 20 Jan 2023 9:07AM $0.160 $0.071 fallen by 55.63%
$37 Imugene Presentation to the JP Morgan Healthcare Conference 9 Jan 2023 9:41AM $0.160 $0.071 fallen by 55.63%
$37 Imugene Receives Vaxinia Ethics Approval in Australia 9 Jan 2023 9:31AM $0.160 $0.071 fallen by 55.63%
$37 Letter to Shareholders 6 Jan 2023 10:28AM $0.160 $0.071 fallen by 55.63%
$37 Notification regarding unquoted securities - IMU 22 Dec 2022 3:36PM $0.153 $0.071 fallen by 53.44%
$37 Notification regarding unquoted securities - IMU 22 Dec 2022 3:32PM $0.153 $0.071 fallen by 53.44%
$37 Ceasing to be a substantial holder 22 Dec 2022 2:23PM $0.155 $0.071 fallen by 54.19%
$37 Ceasing to be a substantial holder 20 Dec 2022 1:48PM $0.153 $0.071 fallen by 53.44%
$37 Change of Director's Interest Notice x6 20 Dec 2022 1:47PM $0.153 $0.071 fallen by 53.44%
$37 Notification of cessation of securities - IMU 16 Dec 2022 5:35PM $0.165 $0.071 fallen by 56.97%
$37 Notification regarding unquoted securities - IMU 16 Dec 2022 5:33PM $0.165 $0.071 fallen by 56.97%
$37 Imugene HER-Vaxx and CF33 Platforms To Feature at ASCO 16 Dec 2022 9:53AM $0.175 $0.071 fallen by 59.43%
$37 Imugene to Present at J.P. Morgan Healthcare Conference 12 Dec 2022 11:38AM $0.183 $0.071 fallen by 61.10%

351 - 375 of 1193 results

Page 15 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.